Venture Capital News
Venture Capital news continually updated from thousands of sources around the net.
40 min ago | Business Journal
"We're seeing a broader mix of investors beyond just VC funding, and our region isn't the only one," says spokesperson Kelly Voelker . "The Angel Capital Association has confirmed that North Carolina is experiencing an increase in angel and other accredited individuals investing in startups and growth-stage companies, which is part of a national trend."
3 hrs ago | Business Journal
It doesn't do Houston any good to bring companies or venture capital to the city, only to have those two leave the city when they succeed, said Walter Ulrich, president of the Houston Technology Center. Ask Walter Ulrich what he thinks Houston's startup ecosystem will look like in 10 years and you'll get a simple answer: The best.
7 hrs ago | Silicon Alley Insider
Choi spent the past few months meeting with a number of venture capitalists for her startup, Mink. Mink is a makeup printing company that teaches anyone how to hack a home printer so it can yield any shade of FDA-approved nail polish, lipstick or eyeshadow they want.
7 hrs ago | The Verona-Cedar Grove Times
The board that runs New Jersey's pension system has reportedly sold its stake in a venture capital firm that has ties to the Republican candidate for governor in Massachusetts this year. The $15 million investment in General Catalyst was sold in August, according to a report published Monday by Fortune magazine.
8 hrs ago | Customer Interaction Solutions
Scholar Rock, a biotechnology company discovering and developing niche modulators that selectively target protein growth factors in the disease microenvironment, today announced a $20 million Series A financing. Proceeds from the financing will be used to advance proprietary niche modulators from preclinical research toward clinical drug development.
8 hrs ago | Business Journal
NewLeaf Symbiotics, a plant science startup operating out of BRDG Park, has closed a $17 million Series B financing round led by Palo Alto, California-based Otter Capital . The money will be used to accelerate NewLeaf's research and development program and ramp up production and bring to market its first biological products.
9 hrs ago | WebWire
Funds advised by Apax Partners today announced that they have agreed to sell their majority ownership stake in the TriZetto Corporation . TriZetto, a provider of world-class healthcare information technology and service solutions, will be sold to Cognizant Technology Solutions Corp for $2.7 billion in cash, subject to customary adjustments.
13 hrs ago | Wall Street Journal
Medical investors once spent a disproportionate amount of their money on diseases affecting the brain, heart and skeleton. Now market pressures and technological advances are driving them to invest across the human body more broadly , according to a special Dow Jones VentureWire report for The Wall Street Journal.
15 hrs ago | Silicon Alley Insider
Beneath the low beams of a converted warehouse in Amsterdam lives a company with many of the attributes of a Silicon Valley startup, except that at less than a year old it has zero venture capital and says it is already making enough money to sustain itself. Fairphone started in 2010 as a campaign against smartphone makers' use of conflict minerals.
Trust in online sellers is needed everywhere. To fill what it calls "the trust gap" for e-commerce companies in emerging markets, a Hong Kong-based startup called TrustedCompany has landed $1 million.
Medical investors once spent a disproportionate amount of their money on diseases affecting the brain, heart and skeleton. Now market pressures and technological advances are driving them to invest across the human body more broadly.
What do the thousands of investment decisions made by early-stage medical investors over the years add up to for us, the public, who stand to benefit from the treatments they finance? Which ailments do startup health companies and venture investors seek to heal, and what body systems do they hope to improve in the process? Disease can appear anywhere in the human body, so investors must choose where to focus. We set out to capture what the human body looks like to venture capitalists: what biological systems they believe hold the most promise, and which organs aren't worth the investment.
The answer in recent years has been the eyes and ears, as investors have poured money into treatments for diseases causing blindness, hearing loss and other diseases affecting an aging population. At the same time, venture capital is pulling back from two historical leaders, heart and orthopedic conditions, in part because of difficulties in bringing medical devices for those ailments to market.
The eyes were the organ that was most attractive to venture capitalists in 2013, raising $848.9 million. Investors have kept up the pace this year, sinking $442.7 million into vision disorders in the first half.
" _ oe * - - Y- ' oe oe -copy-635x357.jpg" class="attachment-large wp-post-image" alt="General Keith Alexander speaks at Tel Aviv University's Cyber Research Center " title="General Keith Alexander speaks at Tel Aviv University's Cyber Research Center " /> Survival of society as we know it in the battle against cyber-criminals and terrorists requires cooperation involving industry academia and investors. That stern warning comes from no less a figure than former NSA Director Gen.
I am the author of Silicon Dragon and Startup Asia . My news, consulting and events group, Silicon Dragon Ventures , publishes venture capital and digital media e-newsletters and develops innovation conferences in the world's tech hotspots.
Tourists on Vishakhapatnam-Araku Valley route will be the first in the country to travel in glass-domed coaches and enjoy the spectacular view. Venture capitalists are taking riskier but smaller bets in early stage funding rounds of startups as they are apprehensive of missing bus, if late.
Updated: Mon Sep 15, 2014 07:32 pm
Copyright © 2014 Topix LLC